Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that the U.S. Food and Drug Administration has granted Fast Track designation to its oncolytic virus pelareorep in combination with bevacizumab and the FOLFIRI chemotherapy regimen for patients with KRAS‑mutant, microsatellite‑stable metastatic colorectal cancer in the second‑line setting.
The Fast Track status is based on a phase II study that reported a 33 % objective response rate, a median progression‑free survival of 16.6 months, and a median overall survival of 27 months for the pelareorep combination, compared with roughly 10 % response, 5.7 months PFS, and 11.2 months OS for standard of care alone. These results represent a substantial improvement in all key clinical endpoints and provide the evidence that the FDA used to award the designation.
Oncolytics plans to launch a randomized, controlled study comparing standard therapy versus standard therapy plus pelareorep, with the first site expected to activate in March 2026 and interim data due by year‑end. The study will confirm the clinical benefit observed in the early data and could support accelerated approval and priority review if the results are replicated in a larger population.
The Fast Track designation is a strategic win that could shorten the regulatory path and open a sizable $3‑$5 billion market for the company’s platform. Pelareorep is an oncolytic virus that selectively infects and kills RAS‑mutant tumor cells while stimulating an anti‑tumor immune response, a mechanism that is particularly relevant for KRAS‑mutant colorectal cancer, a population with limited treatment options.
CEO Jared Kelly said the designation “validates our focus on pelareorep as a platform immunotherapy for gastrointestinal cancers” and added that the combination “has the potential to help a meaningful number of patients.” He emphasized that the Fast Track status “provides a critical regulatory advantage that could accelerate the availability of a new treatment for a large unmet‑need patient group.”
Oncolytics is a clinical‑stage biopharmaceutical company with no revenue and a history of net losses. The Fast Track designation is therefore a significant milestone that may improve investor confidence and support future fundraising efforts, while also reinforcing the company’s strategy of developing pelareorep across multiple gastrointestinal indications, including a prior Fast Track designation for pancreatic cancer.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.